BackZiopharm Oncology Overview

Ziopharm Oncology Minority Interest

Ziopharm Oncology's minority interest is $0.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$0.00

Peer trimmed avg / median

Loading

Ziopharm Oncology Minority Interest History

Loading

Ziopharm Oncology vs. peers: Minority Interest Comparison

Loading

Ziopharm Oncology Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ziopharm Oncology (ZIOP) FAQ

As of the most recent data (June 2026), ZIOP shows a minority interest of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ZIOP's minority interest is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Ziopharm Oncology is outperforming or lagging.

Tracking ZIOP's minority interest over time shows whether Ziopharm Oncology is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this minority interest page, Stockcircle has Ziopharm Oncology's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect minority interest (currently $0) with ownership activity and broader fundamentals.

Ziopharm Oncology's minority interest is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.